表皮生长因子受体酪氨酸激酶抑制剂ZD1839对宫颈癌细胞的作用
Effect of Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor ZD1839 on Cervical Carcinoma Cells
-
摘要: 目的探讨选择性表皮生长因子受体酪氨酸激酶抑制剂ZD1839对宫颈癌细胞的作用。方法以宫颈鳞癌Siha细胞,腺癌Hela细胞为研究对象,利用MTT法检测ZD1839单药使用以及与顺铂联用分别对Siha和Hela细胞的增殖抑制作用。采用Burgi法分析联合用药的效果,并用流式细胞仪检测Siha和Hela细胞的细胞周期分布及凋亡率改变。结果单独使用ZD1839能够抑制Siha、Hela细胞的增殖,其IC50值分别是1.48μmol/L、2.67μmol/L,而且抑制作用呈剂量依赖性。ZD1839能增强顺铂对Siha、Hela细胞的抑制作用,Burgi修正公式所得Q值分别为1.06±0.03(Siha)、1.13±0.01(Hela)。ZD1839使G0/G1期细胞增加,S期细胞减少,细胞凋亡率增加。结论ZD1839能够抑制宫颈癌细胞的增殖,并且能够增强顺铂对宫颈癌细胞的抑制作用,该抑制作用可能与其使肿瘤细胞停滞于G1期和诱导肿瘤细胞的凋亡有关。Abstract: Objective To investigate the effect of a selective epidermal growth factor receptor(EGFR) ZD1839 on cervical carcinoma cells. Methods The effect of ZD1839 on cervical carcinoma cells(Siha,Hela) was determined by MTT assay.The effect of ZD1839 combined with cisplatin(DDP) on cervical carcinoma cells was also evaluated.Burgi formula was adopted to analyze combination effect.The distribution of cell cycle and cell apoptosis rate were analyzed by flow cytometry. Results The proliferation of cervical carcinoma cel...
下载:
